North America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country
The North America gastrointestinal drugs market is expected to reach US$ 31,664.45 million by 2027 from US$ 21,292.53 million in 2019; it is estimated to grow at a CAGR of 5.2% from 2020 to 2027.
Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the Gastrointestinal Drugs market growth in North America.
Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.
Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. Western countries, such as the US, and Canada, are witnessing a high GI incidence rate due to increasing obesity in the adult population and less consumption of dietary fibers. As per the Centers for Disease Control and Prevention, in 2018, the number of visits to physician offices with the digestive system's diseases as the primary diagnosis was 22.4 million in the US. The incidence and prevalence of IBS have increased in the last few decades. As per the International Foundation for Gastrointestinal Disorders, IBS is the most common functional GI disorder with a prevalence rate of 10–15%. There are around 2.4–3.5 million physician visits for IBS annually in the US. As per the Crohn’s & Colitis Foundation of America, IBS affects approximately 1.6 million Americans. Around 70,000 new cases of IBD are diagnosed every year in the US. Apart from the US, other countries are also witnessing increasing burden of chronic digestive diseases due to the aging population and lifestyle factors such as rising obesity and heavy alcohol consumption. Thus, the factors mentioned above are driving the adoption of GI drugs during the forecast period.
North America has been witnessing a growing number of COVID-19 cases since its outbreak. Supply chain disruptions associated with this pandemic situation will ultimately affect the sales of products for short period. However, the OTC supply of gastrointestinal drug has been continuous in the pandemic as medical shops are allowed to open though everything is locked down. Several companies are cutting their clinical trial activities in response to the COVID-19 pandemic. However, in long run, market is expected to boost the demand of gastrointestinal drugs in the forecasted period. Therefore, growing demand for the constipation treatment in North America in long-term period is likely to boost the growth of the constipation treatment market.
Mexico Gastrointestinal Drugs Market, Revenue and Forecast to 2027 (US$ Mn)
Get more information on this report :
NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- US
- Canada
- Mexico
Company Profiles
- Johnson and Johnson Services, Inc.
- Bausch Health
- AbbVie Inc.
- LEXICON PHARMACEUTICALS, INC
- Takeda Pharmaceutical Company Limited
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Gastrointestinal Drugs Market – By Drug Class
1.3.2 North America Gastrointestinal Drugs Market – By Route of Administration
1.3.3 North America Gastrointestinal Drugs Market – By Application
1.3.4 North America Gastrointestinal drugs Market – By Distribution Channel
1.3.5 North America Gastrointestinal drugs Market – By Country
2. North America Gastrointestinal Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Gastrointestinal Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Gastrointestinal Drugs Market - North America PEST Analysis
4.3 Expert Opinion
5. North America Gastrointestinal Drugs Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Increase in Development of Biologics
5.2 Market Restraints
5.2.1 Side Effects Associated With The Drugs
5.3 Market Opportunities
5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
5.4 Future Trends
5.4.1 Emergence of Biosimilars
5.5 Impact Analysis
6. Gastrointestinal Drugs Market – North America Analysis
6.1 North America Gastrointestinal Drugs Market Revenue Forecasts and Analysis
7. North America Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class
7.1 Overview
7.2 North America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
7.2.1 North America Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 North America Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Antidiarrheal and Laxatives
7.4.1 Overview
7.4.2 North America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Anti-Inflammatory Drugs
7.5.1 Overview
7.5.2 North America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Antiemetic and Antinauseants
7.6.1 Overview
7.6.2 North America Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Biologics
7.7.1 Overview
7.7.2 North America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
7.8 Others
7.8.1 Overview
7.8.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. North America Gastrointestinal Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 North America Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)
8.2.1 North America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
8.3 Oral
8.3.1 Overview
8.3.2 North America Oral Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parenteral
8.4.1 Overview
8.4.2 North America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
9. North America Gastrointestinal Drugs Market Analysis – By Application
9.1 Overview
9.2 North America Gastrointestinal Drugs Market, By Application 2019-2027 (%)
9.2.1 North America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)
9.3 Inflammatory Ulcerative Colitis
9.3.1 Overview
9.3.2 North America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Crohn's Disease
9.4.1 Overview
9.4.2 North America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Irritable Bowel Syndrome
9.5.1 Overview
9.5.2 North America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Gastroenteritis
9.6.1 Overview
9.6.2 North America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Celiac Disease
9.7.1 Overview
9.7.2 North America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.8 Others
9.8.1 Overview
9.8.2 North America Others Market Revenue and Forecasts to 2027 (US$ Mn)
10. North America Gastrointestinal Drugs Market Analysis – By Distribution Channel
10.1 Overview
10.2 North America Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)
10.2.1 North America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
10.3 Hospital Pharmacies
10.3.1 Overview
10.3.2 North America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Retail Pharmacies
10.4.1 Overview
10.4.2 North America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Online Pharmacies
10.5.1 Overview
10.5.2 North America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
11. Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027
11.1.1 Overview
11.1.2 North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.3 North America: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.4 North America: Gastrointestinal Drugs Market, by Route of Administration, 2018–2027 (USD Million)
11.1.5 North America: Gastrointestinal Drugs Market, by Application, 2018–2027 (USD Million)
11.1.6 North America: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.7 North America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
11.1.8 US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 US: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.8.3 US: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.8.4 US: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.8.5 US: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.9 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Canada: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.9.3 Canada: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.9.4 Canada: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.9.5 Canada: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.10 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Mexico: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.10.3 Mexico: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.10.4 Mexico: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.10.5 Mexico: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
12. Impact of COVID-19 Pandemic on North America Gastrointestinal drugs Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1 Johnson and Johnson Services, Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Bausch Health
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.3.1 Financial Overview
13.3.2 SWOT Analysis
13.3.3 Key Developments
13.4 AbbVie Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 LEXICON PHARMACEUTICALS, INC
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Takeda Pharmaceutical Company Limited
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.7.1 Financial Overview
13.7.2 SWOT Analysis
13.7.3 Key Developments
14. Appendix
14.1 Glossary of Terms
LIST OF TABLES
Table 1. North America Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)
Table 2. North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 3. North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 4. North America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
Table 5. North America Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 6. North America Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 7. North America Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 8. North America Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. US Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 10. US Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 11. US Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 12. US Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Canada Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 14. Canada Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. Canada Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 16. Canada Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. Mexico Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 18. Mexico Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 19. Mexico Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 20. Mexico Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. Glossary of Terms, Gastrointestinal Drugs Market
LIST OF FIGURES
Figure 1. Gastrointestinal Drugs Market Segmentation
Figure 2. North America Gastrointestinal Drugs Market Overview
Figure 3. Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. North America Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)
Figure 6. Gastrointestinal Drugs Market - North America PEST Analysis
Figure 7. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint
Figure 8. North America Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. North America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
Figure 10. North America Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. North America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. North America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. North America Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. North America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. North America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. North America Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)
Figure 17. North America Oral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. North America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. North America Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)
Figure 20. North America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. North America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. North America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. North America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. North America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. North America Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. North America Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)
Figure 27. North America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. North America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. North America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. North America: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 31. North America Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 32. North America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
Figure 33. US: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in North American Countries
The List of Companies - North America Gastrointestinal Drugs Market
- Johnson and Johnson Services, Inc.
- Bausch Health
- AbbVie Inc
- LEXICON PHARMACEUTICALS, INC
- Takeda Pharmaceutical Company Limited
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America gastrointestinal drugs market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America gastrointestinal drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.